Abstract:The entire nucleotide sequences were determined for hepatitis B virus (HBV) genotype B (HBV/B) genomes extracted from five patients in the Philippines and designated GenBank AB219426, AB219427, AB219428, AB219429 and AB219430. The serotype of the first four isolates was ayw and that of GenBank AB219430 was adw. Divergences of entire sequences were 1?0-2?0 % between the first four isolates and 3?8-4?2 % between these four and GenBank AB219430. Phylogenetic-tree analysis revealed that, worldwide, HBV/B comprises… Show more
“…Subgenotypes (subgroups) have been identified for certain HBV genotypes (7,9,15,20,22,26). HBV/C has been classified into five subgenotypes, HBV/C1 to HBV/C5 (7,9,26,30), as has HBV/D, into HBV/D1 to HBV/D5 (3,5,22,28).…”
mentioning
confidence: 99%
“…Subgroup Bj is found mostly in East Asia, including Japan, while subgroup Ba is found throughout Asia and has recombination with HBV/C in the C gene (31). More recently, subgroup Ba has been further divided into four subgenotypes, HBV/B2 to HBV/B5, with subgroup Bj being renamed subgenotype HBV/B1 (20,26,30).…”
“…Subgenotypes (subgroups) have been identified for certain HBV genotypes (7,9,15,20,22,26). HBV/C has been classified into five subgenotypes, HBV/C1 to HBV/C5 (7,9,26,30), as has HBV/D, into HBV/D1 to HBV/D5 (3,5,22,28).…”
mentioning
confidence: 99%
“…Subgroup Bj is found mostly in East Asia, including Japan, while subgroup Ba is found throughout Asia and has recombination with HBV/C in the C gene (31). More recently, subgroup Ba has been further divided into four subgenotypes, HBV/B2 to HBV/B5, with subgroup Bj being renamed subgenotype HBV/B1 (20,26,30).…”
“…The inclusion criteria of these patients strictly followed those of the phase III clinical trial by Bristol-Myers Japan Inc. (Tokyo); briefly, both i) the presence of active HBV viremia (> 10 5 copy/mL), and ii) the presence of pathologily than genotype C (HBV/C), and those infected with HBV/B appear to have a better prognosis (Kikuchi 2000;Orito et al 2001). At present, HBV genotype B (HBV/B) has been clustered into five subgenotypes (Nagasaki et al 2006a). Lamivudine, the first approved orally administered nucleotide analogue, is well known for its safety and effectiveness in the treatment of HBV infections, including HBV cirrhosis, regardless of the HBV genotype (Yao and Bass 2000;Yao et al 2001;Yuen et al 2003).…”
“…38,83,103,143,152,167 HBV/C has been classified into five subgenotypes, HBV/C1 to HBV/ C5, 38,83,167,190 HBV/D into HBV/D1 to HBV/D5. 21,31,152,172 Similarly, HBV/B was initially classified into two subgroups, Bj and Ba.…”
mentioning
confidence: 99%
“…197 More recently, subgroup Ba has been further divided into four subgenotypes, HBV/B2 to HBV/B5, with subgroup Bj being renamed subgenotype HBV/B1. 143,167,190 …”
Hepatitis B virus (HBV) infection remains a global health problem and a public health threat in the present era. It is estimated that 2 billion people are infected with HBV and 350 million people suffer from chronic HBV infection in the world. India is a prosperous country in Asia and has peculiar geographical presence which is responsible for evasion of this land by traders and invaders in past and resulted in gene influx due to invasion and/or anthropological migrations in the past. Moreover, recent increase in trade, trafficking and use of illicit drugs has also considerably influenced the epidemiology of HBV in different parts of India. However, data on the genotypes/subgenotypes diversity of HBV in India is scanty. In this manuscript, the information available on the genetic diversity of HBV genotypes and subgenotypes in India and in world and their relationship with the disease progression has been reviewed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.